Supernus to Acquire Adamas and Its Therapies, Gocovri and Osmolex ER

Supernus to Acquire Adamas and Its Therapies, Gocovri and Osmolex ER

309092

Supernus to Acquire Adamas and Its Therapies, Gocovri and Osmolex ER

Two established Parkinson’s disease (PD) treatments — Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride) — will move to Supernus’ Pharmaceuticals when it completes an agreement now in place for it to acquire Adamas Pharmaceutical. The $450 million agreement — $50 million of which is contingent upon certain Gocovri sale milestones  being achieved — is expected to be finalized later this year or early in 2022. “This acquisition represents a significant step to further build a strong and…

You must be logged in to read/download the full post.